These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3882141)

  • 41. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?
    Storb R; Leisenring W; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan KM; Witherspoon R; Pettinger M; Bensinger W; Buckner CD; Clift R; Flowers ME; Hansen JA; Pepe M; Chauncey T; Sanders J; Thomas ED
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):194-201. PubMed ID: 9360781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation.
    Nevill TJ; Tirgan MH; Deeg HJ; Klingemann HG; Reece DE; Shepherd JD; Barnett MJ; Phillips GL
    Bone Marrow Transplant; 1992 May; 9(5):349-54. PubMed ID: 1617319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.
    Paquette RL; Tran L; Landaw EM
    Bone Marrow Transplant; 1998 Aug; 22(4):351-7. PubMed ID: 9722070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. International Bone Marrow Transplant Registry.
    Lancet; 1989 Mar; 1(8637):535-7. PubMed ID: 2564066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD; Shore TB; Reece DE; Barnett MJ; Klingemann HG; Buskard NA; Phillips GL
    Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients.
    Dieterle A; Gratwohl A; Nizze H; Huser B; Mihatsch MJ; Thiel G; Tichelli A; Signer E; Nissen C; Speck B
    Transplantation; 1990 Jun; 49(6):1093-100. PubMed ID: 2193442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract]   [Full Text] [Related]  

  • 55. [A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow].
    Chen H; Ji S; Wang H
    Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):760-3. PubMed ID: 11930684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An increased risk of relapse in cyclosporin-treated compared with methotrexate-treated patients: long-term follow-up of a randomized trial.
    Bäckman L; Ringdén O; Tollemar J; Lönnqvist B
    Bone Marrow Transplant; 1988 Sep; 3(5):463-71. PubMed ID: 2847843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients.
    Kennedy MS; Yee GC; Mcguire TR; Leonard TM; Crowley JJ; Deeg HJ
    Transplantation; 1985 Sep; 40(3):249-53. PubMed ID: 3898489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
    Weaver CH; Clift RA; Deeg HJ; Storb R; Appelbaum FR; Bensinger W; Doney K; Hansen JA; Martin PO; Sanders J
    Bone Marrow Transplant; 1994 Dec; 14(6):885-93. PubMed ID: 7711667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.